The COVID-19 Pandemic Has Disrupted Cancer Trials
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.
Pharmacy Times® interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers and medical director at Ann B. Barshinger Cancer Institute, Penn Medicine in Lancaster PA about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trial.
The full conversation can be found in the video above.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025